Race to End Duchenne Announces 2024 Racing for Every Future Team Award Winner: Team Michael James
ORLANDO, Fla., Jan. 6, 2024 /PRNewswire/ — Race to End Duchenne, the endurance fundraising program of Parent Project Muscular Dystrophy (PPMD), is pleased to announce Team Michael James as the recipient of the 2024 Racing for Every Future Team Award. This award was presented at the Walt Disney
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Roblox Corporation – RBLX
NEW YORK, Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Roblox Corporation (“Roblox” or the “Company”) (NYSE: RBLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7
HAVIT Debuts Affordable Headphones with Spatial Audio and Hi-Res Audio Certification
GUANGZHOU, China, Jan. 6, 2024 /PRNewswire/ — HAVIT, a leading smart technology company specializing in audio devices, is set to unveil its latest innovative products at CES 2024. With a commitment to serving users through innovative technology, HAVIT’s self-developed SPACE NC ZERO wirel
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Generac Holdings, Inc. – GNRC
NEW YORK, Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Generac Holdings, Inc. (“Generac” or the “Company”) (NYSE: GNRC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ex
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Paycom Software, Inc. – PAYC
NEW YORK , Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Paycom Software, Inc. (“Paycom” or the “Company”) (NYSE: PAYC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ex
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FMC Corporation – FMC
NEW YORK, Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of FMC Corporation (“FMC” or the “Company”) (NYSE: FMC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Beauty Health Company – SKIN
NEW YORK, Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of The Beauty Health Company (“Beauty Health” or the “Company”) (NASDAQ: SKIN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Veradigm Inc. – MDRX
NEW YORK, Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Veradigm Inc. (“Veradigm” or the “Company”) (NASDAQ: MDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 79
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. – SCYX
NEW YORK, Jan. 6, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 79
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and SpainEncouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosingInitiation o
